- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT01534416
Effect of Paracervical Block on Post Operative Pain in Laparoscopic Gynecologic Surgery
Use of Paracervical Block in Laparoscopic Gynecologic Surgery: A Randomized Controlled Trial
Aperçu de l'étude
Statut
Intervention / Traitement
Description détaillée
A variety of traditionally open surgical procedures have recently become minimally invasive through the use of laparoscopic technology. Gynecologic surgeries are no exception. However, some gynecologic laparoscopic procedures are associated with significant post-operative pain, necessitating prolonged hospitalization, use of post-operative opioids, and in some cases, the development of chronic post-operative pain. Prolonged hospitalization and use of opioids pose important patient safety concerns, such as increased risk of hospital borne illnesses and medication errors; in addition, opioids may cause respiratory depression and addiction. Given the rising cost of health care there is also an economic incentive to eliminate the need for hospital admission due to post-operative pain.
Preemptive analgesia involves nerve blockade or administration of pain medication systemically prior to incision to reduce post-procedure pain. Paracervical blockade is a form of preemptive analgesia. Paracervical blocks have been demonstrated to be safe and effective for obstetrical procedures in reducing post-operative pain since the 1970s. Recently they have also been shown to be efficacious for reducing post-operative pain in vaginal hysterectomy (Long et al, Int Urogynecol J (2009) 20:5-10).
For the present investigation, we intend to study the effectiveness of paracervical blockade for laparoscopic and robotic-assisted laparoscopic gynecological surgery. We hypothesize that paracervical blockade prior to surgical incision will lessen levels of post-operative pain, reduce use of opioids, and decrease the number of patients requiring hospitalization for pain control. We also hypothesize that the effects may be longer lasting than the immediate post-operative period and may decrease the amount of time to return to normal activity after surgery.
Using anecdotal evidence from the primary investigator, Dr. Ascher-Walsh the rate of hospitalization for laparoscopic hysterectomy (laparoscopic-assisted vaginal hysterectomy, total laparoscopic hysterectomy, laparoscopic assisted supracervical hysterectomy) is approximately 67%. In this study, we wish to decrease hospitalization with the paracervical block by 50%, thus obtaining an overall post-operative hospitalization rate of 33%. For robotic-assisted laparoscopic myomectomy, the rate of hospitalization is 50%. We wish to decrease this by 50% as well. Overall we are aiming to achieve a rate of 30% for post-operative hospitalization for pain control for laparoscopic hysterectomies and robotic myomectomies combined.
Type d'étude
Inscription (Réel)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
New York
-
New York, New York, États-Unis, 10029
- Icahn School of Medicine at Mount Sinai
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Female
- Age 18 or older
- Scheduled for robotic-assisted laparoscopic myomectomy or laparoscopic hysterectomy, including total and supracervical hysterectomy, laparoscopic-assisted vaginal hysterectomy
- Surgery being performed for benign disease
Exclusion Criteria:
- Male
- Women under 18 years old
- Pregnancy
- Suspected or known malignant disease
- Immunocompromised
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Soins de soutien
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Quadruple
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Bupivacaine
Subjects receive paracervical block with bupivacaine-epinephrine
|
Subjects are injected paracervically with 10 ml of 0.5% bupivacaine with 1:200000 units epinephrine prior to surgical incision.
Autres noms:
|
|
Comparateur placebo: Saline
Subjects receive paracervical injection of normal saline
|
Subjects are injected paracervically with 10 ml of normal saline prior to surgical incision.
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Number of Participants With Hospital Admission for Postoperative Pain Control
Délai: Four hours after conclusion of surgery
|
Unplanned hospital admissions and the hospital admissions at the request of the patients for pain management
|
Four hours after conclusion of surgery
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Postoperative Pain Score
Délai: 1and 2 hour postoperatively
|
Postoperative pain levels assessed using the visual analogue pain scale.
This scale pairs faces with numbers 1-10, with 1 being no pain and 10 being extreme pain.
In the PACU pain assessed using this scale by the nursing staff.
|
1and 2 hour postoperatively
|
|
Postoperative Pain Score
Délai: 1, 2, 4 hour postoperatively, Day 1 post operatively, Day 2 postoperative
|
Postoperative pain levels assessed using the visual analogue pain scale.
This scale pairs faces with numbers 1-10, with 1 being no pain and 10 being extreme pain.
In the PACU pain assessed using this scale by the nursing staff.
On postoperative days 1 and 2 the subjects self-reported their pain level.
|
1, 2, 4 hour postoperatively, Day 1 post operatively, Day 2 postoperative
|
|
Postoperative Day Pain Medication Use
Délai: Postoperative days 0-10
|
Numbers of Patients Using Pain Medication on Postoperative Days 1-10.
The subjects recorded at home the type and amount of pain medication they use for 10 days postoperatively.
|
Postoperative days 0-10
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Charles Ascher-Walsh, MD, Icahn School of Medicine at Mount Sinai
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Processus pathologiques
- Complications postopératoires
- La douleur
- Manifestations neurologiques
- Douleur, Postopératoire
- Effets physiologiques des médicaments
- Dépresseurs du système nerveux central
- Agents du système nerveux périphérique
- Agents du système sensoriel
- Anesthésiques
- Anesthésiques locaux
- Bupivacaïne
Autres numéros d'identification d'étude
- GCO 11-0021
- HS# 11-00013
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .